EurekAlert! reports that the Global Antibiotic Research & Development Partnership (GARDP) and Penta, the pediatric infectious disease research network, have joined forces to address drug-resistant infections in children. A key objective is to accelerate pediatric development of antibiotic treatments including clinical trials designed to meet regulatory requirements as well as trials with a focus on public health interventions to inform treatment guidelines.
The partners report that globally more than 3 million childhood deaths annually result from infectious diseases such as pneumonia and sepsis. Most recently it was found that children in Europe infants under one bear the highest burden of drug-resistant infections. Impacts are higher in low- and middle-income countries. GARDP and Penta’s partnership consolidates plans to help overcome this gap in care through the development of a global children’s antibiotic platform. Building on Penta’s international network of clinical trial sites and pediatric experts, the platform objectives include to: develop streamlined pediatric development plans acceptable to regulatory authorities; accelerate regulatory approval of treatments by ensuring children’s trials are started as early as possible; and incorporate innovative designs to maximize the information that can be gained from each trial.
Global Antibiotic Research & Development Partnership (GARDP)
GARDP is a not-for-profit research and development (R&D) organization that addresses global public health needs by developing and delivering new or improved antibiotic treatments, while endeavoring to ensure their sustainable access.
The PENTA-ID Network reaches almost every area of the world, including clinical sites and collaborators in Asia, Africa and the Americas, growing steadily since its initiation in Europe. Our members also cover an incredible depth and breadth of expertise and specialties, including clinicians, trialists, basic researchers, educators and advocates.
We leverage this diversity in conducting world class clinical studies, training programs and infrastructure development initiatives in the area of pediatric infectious disease, all with the aim of improving the lives of women and children through generation and application of scientific knowledge.